Moderna has shipped the first batch of the company’s rapidly developed coronavirus vaccine to researchers at the National Institute of Allergy and Infectious Diseases.
Researchers look to messenger RNA encased in nanoparticles, DNA plasmids, molecular clamps, and other approaches as they rush to design a vaccine against the new coronavirus.
As HIV drugs, stem cells and traditional Chinese medicines vie for a chance to prove their worth, the World Health Organization attempts to bring order to the search.
Via a five-year collaborative research pact, Harvard and Guangzhou Institute will split $115 million in research funding provided by China Evergrande Group.
Moderna has shipped the first batch of the company’s rapidly developed coronavirus vaccine to researchers at the National Institute of Allergy and Infectious Diseases.
Researchers look to messenger RNA encased in nanoparticles, DNA plasmids, molecular clamps, and other approaches as they rush to design a vaccine against the new coronavirus.
As HIV drugs, stem cells and traditional Chinese medicines vie for a chance to prove their worth, the World Health Organization attempts to bring order to the search.
Via a five-year collaborative research pact, Harvard and Guangzhou Institute will split $115 million in research funding provided by China Evergrande Group.
